Organization (Industry)
Revolution Medicines, Inc.
ClinicalTrials.gov lists Revolution Medicines, Inc. as lead sponsor of 20 trials. It has 133 active development programs and 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 8 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Revolution Medicines, Inc.: 20 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 14 |
| Pancreatic Neoplasms | 14 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Colorectal Neoplasms | 8 |
| Neoplasm Metastasis | 6 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
Prediction, not a registry value: median of 36 months from start to primary completion across 15 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (133)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Daraxonrasib | Pancreatic Neoplasms | Phase 3 | 10 |
| Daraxonrasib | Lung Neoplasms | Phase 3 | 7 |
| Daraxonrasib | Carcinoma, Non-Small-Cell Lung | Phase 3 | 7 |
| GEMCITABINE | Pancreatic Neoplasms | Phase 3 | 5 |
| NAB paclitaxel | Pancreatic Neoplasms | Phase 3 | 5 |
Showing 5 of 133 active programs.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| NAB paclitaxel | 5 |
| GEMCITABINE | 5 |
| OXALIPLATIN | 2 |
| Irinotecan | 2 |
| PEMBROLIZUMAB | 2 |
Showing 5 of 15 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 1 of 3 on time (n=3) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Science (New York, N.Y.) | 2 |
| Cancer discovery | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Journal of medicinal chemistry | 1 |
| Nature | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 37 | 30 | 2025-11-11 |
SEC-reported annual financials (9)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 0 | -1,131,301,000 | 987,332,000 |
| 2024 | 0 | -600,093,000 | 592,225,000 |
| 2023 | 11,580,000 | -436,367,000 | 423,144,000 |
| 2022 | 35,380,000 | -248,705,000 | 253,073,000 |
| 2021 | 29,390,000 | -187,091,000 | 186,948,000 |
| 2020 | 42,983,000 | -108,159,000 | 132,252,000 |
| 2019 | 50,041,000 | -47,664,000 | 91,755,000 |
| 2018 | 20,165,000 | -41,789,000 | 51,084,000 |
| 2017 | not reported | not reported | not reported |
Financing and grant events (29)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-17 | Debt financing | 500,000,000 | Sec extracted |
| 2026-04-14 | Public offering | 1,650,400,000 | Sec extracted |
| 2026-04-14 | Debt financing | not disclosed | Sec extracted |
| 2026-02-25 | Follow-on offering | 1,000,000,000 | Edgar offerings |
| 2025-06-23 | Royalty / licensing | 250,000,000 | Sec extracted |
Showing 5 of 29 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 59.0% | not disclosed |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Cholangiocarcinoma Foundation | Co sponsors trial with | 1 |
| Synnovation Therapeutics, Inc. | Co sponsors trial with | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Co sponsors trial with | 1 |
| Nicholas Butowski | Co sponsors trial with | 1 |
Latest dated events (91)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-30 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 91 events.
Biomarker capability evidence (81)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ATF6B | Trial sponsor | Named in trial inclusion criteria |
| ATF6B | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 81 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.